The company said it will use the funds to repay the $75 million outstanding under its 2018 Note Purchase Agreement, to expand internationally, and on general operations.
The health technology firm is proposing a new software solution that would standardize coding in genetic testing, but a more predictable system would also narrow variability in test pricing.
Get the latest news from Biovica, Invitae, and Agilent Technologies for the week of 8/30/19.
In response to CMS reopening its national coverage determination to address its germline testing policy, stakeholders point out areas of concern and confusion.
The San Francisco-based medical genetics firm generated $53.5 million in revenues in the second quarter, beating analysts' consensus estimate of $50.7 million.
Of the 27 companies in the index, 12 firms' share prices retreated last month, 14 companies' stocks increased, and one firm's share value was flat.
The first application of the technology will be for noninvasive prenatal screening followed by cancer liquid biopsy testing.
Other big gainers last month included Accelerate Diagnostics and Natera, and share prices of 23 of the 27 companies in the index increased month over month.
Get the latest news from Invitae, Exact Sceicnes, Danaher, SkylineDx, Personalis, and Seegene for the week of 6/28/19.
Senators said they'll narrow the draft bill containing changes to US patent law before submitting it to the Senate Judiciary Committee in July.